18Jan 2024
ADAPT+ Study Shows Long-Term Success of Efgartigimod in Generalized Myasthenia Gravis Treatment

ADAPT+ Study Shows Long-Term Success of Efgartigimod in Generalized Myasthenia Gravis Treatment

ADAPT+ study evaluates efgartigimod's long-term safety, tolerability, and efficacy in adults with generalized myasthenia gravis (gMG). In this open-label, single-arm extension of the pivotal phase 3 ADAPT study, participants received up to 17 treatment cycles over 548 days. Most experienced treatment-emergent adverse events, with headache and COVID-19 being prominent. Clinically meaningful improvements were observed in Myasthenia Gravis-Activities of Daily Living and Quantitative Myasthenia Gravis scores. The results affirm efgartigimod's significant clinical benefits, supporting its extended use with an individualized dosing approach for gMG treatment.

  • #neurology

Like

Save

Share